abbvie

September 19, 2019

The Honorable TJ Donovan
Attorney General
State of Vermont
109 State Street
Montpelier, VT 05609

Sent via e-mail to AGO.DrugCosts@vermont.gov

Dear Attorney General Donovan,

As follow-up to our notification sent on August 23, 2019, and per 18 V.S.A. § 4637(c), AbbVie is providing the following information related to the launch of RINVOQ™(upadacitinib). Per 18 V.S.A. § 4637(d), the information provided below is limited to information that is in the public domain or publicly available.

1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;

- RINVOQ will be marketed to adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
- The recommended dose of RINVOQ is 15mg once daily. The WAC price of a thirty-tablet bottle of RINVOQ is $4,916.47. The annual wholesale acquisition cost of RINVOQ is $59,000, which is lower than the current leading treatments for moderate to severe rheumatoid arthritis.
- RINVOQ is under review by the European Medicines Agency, as well as regulatory authorities in Canada and Japan, for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

abbvie

2) The estimated volume of patients who may be prescribed the drug

Based upon an observational, retrospective, cross-sectional study using data from the US administrative health insurance claims databases (Truven Health MarketScan® and IMS PharMetrics Plus database), it is estimated that approximately 1.3 million adults in the United States have rheumatoid arthritis. See e.g., Hunter T., et al., *Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014,* Rheumatol. Int., 37(9): 1551-1557 (2017). RINVOQ may be prescribed for that fraction of adults with moderately to severely active rheumatoid arthritis who have had inadequate response or intolerance to methotrexate.

3) Breakthrough therapy designation or priority review by FDA

RINVOQ was not granted breakthrough designation or priority review by the FDA.

4) Date and price of acquisition, if the drug was not developed by the manufacturer

RINVOQ was developed by AbbVie.

Sincerely,

Matthew Williams
Vice President, State Government Affairs